Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma

NCT05498792 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced or Metastatic Melanoma

Interventions

DRUG: CBL0137
DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

Fox Chase Cancer Center

Collaborators

[object Object]